Company: LNAI
Filing Date: 2025-03-06
Form Type: 425
Source: 0001731122-25-000356
Chunk: 1

Company: Lunai Bioworks Inc.
Filing Date: 2025-03-06
Form: 425
Chunk 1
---
 Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

| Item 1.01 | Entry into a Material Definitive Agreement. |

As previously reported, on January
1, 2025, Renovaro, Inc., a Delaware corporation (“Renovaro”), entered into binding letter of intent (the “LOI”)
with Predictive Oncology Inc., a Delaware corporation (“Predictive Oncology”), with respect to the proposed acquisition
of all of the capital stock of Predictive Oncology by Renovaro (the “Transaction”). On February 28, 2025, Renovaro
entered into an extension agreement with Predictive Oncology (the “Extension Agreement”), pursuant to which the parties
amended the LOI to (i) eliminate Renovaro’s obligation to acquire certain shares of Predictive Oncology’s common stock and
(ii) extend the outside termination date of the LOI from February 28, 2025 to March 31, 2025. Additionally, pursuant to the Extension
Agreement, Renovaro acquired 467,290 shares of Predictive Oncology’s common stock for an aggregate purchase price of $500,000 and
agreed to purchase an additional 901,298 shares of Predictive Oncology common stock for an aggregate of $964,389 upon, and subject to,
the execution of a definitive agreement in respect of the Transaction.

The foregoing description of the
Extension Agreement is only a summary and is qualified in its entirety by reference to the complete text of the Extension Agreement, which
is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 1.01.

Additional Information and Where to Find It:

This communication may be deemed
to relate to a proposed acquisition of Predictive Oncology by Renovaro. In connection with the proposed acquisition, Renovaro and Predictive
Oncology intend to file relevant materials with the Securities and Exchange Commission (SEC), including a Registration Statement on Form
S-4 to be filed by Renovaro that will include a preliminary proxy statement of Predictive Oncology and also constitute a prospectus with
respect to the shares of equity